Europeiska unionen - svenska - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - carcinom, non-small cell lung - antineoplastiska medel - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Europeiska unionen - svenska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanom - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.

Europeiska unionen - svenska - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastiska medel - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Europeiska unionen - svenska - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinom, non-small cell lung - antineoplastiska medel - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pfizer ab - alprostadil - pulver och vätska till injektionsvätska, lösning - 10 mikrogram - bensylalkohol hjälpämne; laktosmonohydrat hjälpämne; alfadex hjälpämne; alprostadil 10 mikrog aktiv substans - alprostadil

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pfizer ab - alprostadil - pulver och vätska till injektionsvätska, lösning - 10 mikrogram - alprostadil 10 mikrog aktiv substans; laktosmonohydrat hjälpämne; alfadex hjälpämne; bensylalkohol hjälpämne - alprostadil

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pfizer ab - alprostadil - pulver och vätska till injektionsvätska, lösning - 20 mikrogram - bensylalkohol hjälpämne; alprostadil 20 mikrog aktiv substans; laktosmonohydrat hjälpämne; alfadex hjälpämne - alprostadil

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pfizer ab - alprostadil - pulver och vätska till injektionsvätska, lösning - 20 mikrogram - alfadex hjälpämne; bensylalkohol hjälpämne; laktosmonohydrat hjälpämne; alprostadil 20 mikrog aktiv substans - alprostadil

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pfizer ab - alprostadil - pulver och vätska till injektionsvätska, lösning - 40 mikrogram - alprostadil 40 mikrog aktiv substans; bensylalkohol hjälpämne; laktosmonohydrat hjälpämne - alprostadil

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pfizer ab - alprostadil - pulver och vätska till injektionsvätska, lösning - 5 mikrogram - bensylalkohol hjälpämne; alprostadil 5 mikrog aktiv substans; laktosmonohydrat hjälpämne - alprostadil